Cargando…
Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss
BACKGROUND: Health systems face challenges to accelerate access to innovations that add value and avoid those unlikely to do so. This is very timely to the field of age-related sensorineural hearing loss (ARHL), where a significant unmet market need has been identified and sizeable investments made...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930912/ https://www.ncbi.nlm.nih.gov/pubmed/35310110 http://dx.doi.org/10.3389/fnins.2022.769983 |
_version_ | 1784671139583229952 |
---|---|
author | Landry, Evie C. Scholte, Mirre Su, Matthew P. Horstink, Yvette Mandavia, Rishi Rovers, Maroeska M. Schilder, Anne G. M. |
author_facet | Landry, Evie C. Scholte, Mirre Su, Matthew P. Horstink, Yvette Mandavia, Rishi Rovers, Maroeska M. Schilder, Anne G. M. |
author_sort | Landry, Evie C. |
collection | PubMed |
description | BACKGROUND: Health systems face challenges to accelerate access to innovations that add value and avoid those unlikely to do so. This is very timely to the field of age-related sensorineural hearing loss (ARHL), where a significant unmet market need has been identified and sizeable investments made to promote the development of novel hearing therapeutics (NT). This study aims to apply health economic modeling to inform the development of cost-effective NT. METHODS: We developed a decision-analytic model to assess the potential costs and effects of using regenerative NT in patients ≥50 with ARHL. This was compared to the current standard of care including hearing aids and cochlear implants. Input data was collected from systematic literature searches and expert opinion. A UK NHS healthcare perspective was adopted. Three different but related analyses were performed using probabilistic modeling: (1) headroom analysis, (2) scenario analyses, and (3) threshold analyses. RESULTS: The headroom analysis shows an incremental net monetary benefit (iNMB) of £20,017[£11,299–£28,737] compared to the standard of care due to quality-adjusted life-years (QALY) gains and cost savings. Higher therapeutic efficacy and access for patients with all degrees of hearing loss yields higher iNMBs. Threshold analyses shows that the ceiling price of the therapeutic increases with more severe degrees of hearing loss. CONCLUSION: NT for ARHL are potentially cost-effective under current willingness-to-pay (WTP) thresholds with considerable room for improvement in the current standard of care pathway. Our model can be used to help decision makers decide which therapeutics represent value for money and are worth commissioning, thereby paving the way for urgently needed NT. |
format | Online Article Text |
id | pubmed-8930912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89309122022-03-19 Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss Landry, Evie C. Scholte, Mirre Su, Matthew P. Horstink, Yvette Mandavia, Rishi Rovers, Maroeska M. Schilder, Anne G. M. Front Neurosci Neuroscience BACKGROUND: Health systems face challenges to accelerate access to innovations that add value and avoid those unlikely to do so. This is very timely to the field of age-related sensorineural hearing loss (ARHL), where a significant unmet market need has been identified and sizeable investments made to promote the development of novel hearing therapeutics (NT). This study aims to apply health economic modeling to inform the development of cost-effective NT. METHODS: We developed a decision-analytic model to assess the potential costs and effects of using regenerative NT in patients ≥50 with ARHL. This was compared to the current standard of care including hearing aids and cochlear implants. Input data was collected from systematic literature searches and expert opinion. A UK NHS healthcare perspective was adopted. Three different but related analyses were performed using probabilistic modeling: (1) headroom analysis, (2) scenario analyses, and (3) threshold analyses. RESULTS: The headroom analysis shows an incremental net monetary benefit (iNMB) of £20,017[£11,299–£28,737] compared to the standard of care due to quality-adjusted life-years (QALY) gains and cost savings. Higher therapeutic efficacy and access for patients with all degrees of hearing loss yields higher iNMBs. Threshold analyses shows that the ceiling price of the therapeutic increases with more severe degrees of hearing loss. CONCLUSION: NT for ARHL are potentially cost-effective under current willingness-to-pay (WTP) thresholds with considerable room for improvement in the current standard of care pathway. Our model can be used to help decision makers decide which therapeutics represent value for money and are worth commissioning, thereby paving the way for urgently needed NT. Frontiers Media S.A. 2022-03-04 /pmc/articles/PMC8930912/ /pubmed/35310110 http://dx.doi.org/10.3389/fnins.2022.769983 Text en Copyright © 2022 Landry, Scholte, Su, Horstink, Mandavia, Rovers and Schilder. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Landry, Evie C. Scholte, Mirre Su, Matthew P. Horstink, Yvette Mandavia, Rishi Rovers, Maroeska M. Schilder, Anne G. M. Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss |
title | Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss |
title_full | Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss |
title_fullStr | Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss |
title_full_unstemmed | Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss |
title_short | Early Health Economic Modeling of Novel Therapeutics in Age-Related Hearing Loss |
title_sort | early health economic modeling of novel therapeutics in age-related hearing loss |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930912/ https://www.ncbi.nlm.nih.gov/pubmed/35310110 http://dx.doi.org/10.3389/fnins.2022.769983 |
work_keys_str_mv | AT landryeviec earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss AT scholtemirre earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss AT sumatthewp earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss AT horstinkyvette earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss AT mandaviarishi earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss AT roversmaroeskam earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss AT schilderannegm earlyhealtheconomicmodelingofnoveltherapeuticsinagerelatedhearingloss |